

DAFTAR PUSTAKA

1. Kementrian Kesehatan RI Pusat Data dan Informasi Kesehatan; Bulan Peduli Kanker Payudara, *infodatin-Kanker*, 2016.
2. Kementerian Kesehatan RI Pusat Data dan Informasi Kesehatan; Stop Kanker, *infodatin-Kanker*, 2015.
3. Ades, F.; Tryfonidis, K.; Zardavas, D.; The Past and Future of Breast Cancer Treatment - From the Papyrus to Individualised Treatment Approaches, *Ecancermedicalscience*, 2017, 11, 746.
4. Radji, M; Pendekatan Farmakogenomik Dalam Pengembangan Obat Baru, *Pharm. Sci. Res*, 2005, 2 (1), 1–11.
5. Murray, G. I.; Patimalla, S.; Stewart, K. N.; Miller, I. D.; Heys, S. D.; Profiling the Expression of Cytochrome P450 in Breast Cancer, *Histopathology*, 2010, 57 (2), 202–211.
6. Levy, R. H.; Cytochrome P450 Isozymes and Antiepileptic Drug Interactions, 1995.
7. Dhaini, H. R., et al; Cytochrome P450 CYP3A4/5 Expression as a Biomarker of Outcome in Osteosarcoma, *J. Clin. Oncology*, 2003, 21 (13), 2481–2485.
8. Zeng, Z.; Andrew, N. W.; Arison, B. H.; Wang, R. W.; Identification of Cytochrome P4503A4 as the Major Enzyme Responsible for the Metabolism of Ivermectin by Human Liver Microsomes, 2000, 313–321.
9. Shahriary, G. M.; et al; CYP2E1 * 5B, CYP2E1 * 6, CYP2E1 * 7B, CYP2E1 * 2, and CYP2E1 * 3 Allele Frequencies in Iranian Populations. *Asian Pacific J. Cancer Prev*, 2012, 13 (12), 6505–6510.
10. Ota, M.; Fukushima, H.; Kulski, J. K.; Inoko, H; Single Nucleotide Polymorphism Detection by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism, *Nat. Protoc*, 2007, 2 (11), 2857–2864.
11. Elens, L.; van Gelder, T.; Hesselink, D. A.; Haufroid, V.; van Schaik, R. CYP3A4 Variant Allele for Personalizing Pharmacotherapy, *Pharmacogenomics*, 2013, 14 (1), 47–62.
12. Teft, W. A.; et al; CYP3A4 and Seasonal Variation in Vitamin D Status in Addition to CYP2D6 Contribute to Therapeutic Endoxifen Level during Tamoxifen Therapy, *Breast Cancer Res. Treat*, 2013, 139 (1), 95–105. (13) Wang, D.; Guo, Y.; Wrighton, S. A.; Cooke, G. E.; Sadee, W. Intronic Polymorphism in CYP3A4 Affects Hepatic Expression and Response to Statin Drugs. *Pharmacogenomics J.* 2011, 11 (4), 274–286.
14. Nieuweboer, A.; Clarke, S. J.; Charles, K. A. Lower CYP3A4 Activity in Cancer Patients , as Measured with Probes Midazolam and Erythromycin, 2012, 137–149.
15. Wang, J. M; et al; Irradiation Induces Up-Regulation of E9 Protein (CD105) in Human Vascular Endothelial Cells, *Int. J. Cancer*, 1995, 62 (6), 791–796.
16. Langdon, S. P; Cancer Cell Culture, 2003, 88.
17. Gurova, K; New Hopes From Old Drugs: Revisiting DNA-Binding Small Molecules as Anticancer Agents, *Future Oncology Rev*, 2009, 1685–1704.
18. Parker, W. B. Enzymology of Purine and Pyrimidine Antimetabolites Used in the Treatment of Cancer, *Chem. Rev*, 2009, 109 (7), 2880–2893.
19. Miftahu, S; Metode Polymerase Change Raaction-Restriction Fragment Length Polymorphism (PCR-RFLP) untuk Deteksi Single Nucleotide Polymorphism (SNP) Gen ERBB2 Pada Pasien Kanker Payudara, 2016.
20. Bu, H; A Literature Review of Enzyme Kinetic Parameters for CYP3A4-Mediated Metabolic Reactions of 113 Drugs in Human Liver Microsomes: Structure-Kinetics Relationship Assessment, *Curr. Drug Meta.* 2006, 7 (3),

- 231–249.
21. Lusiastuti, A. M.; Seeger, H.; Sugiani, D.; Mufidah, T.; Novita, H. Deteksi Polymorfisme dengan Substitusi Nukleotida Tunggal pada *Streptococcus Agalactiae* Isolat Lokal Indonesia, *Media Akuakultur*, 2015, 10 (2), 91.
 22. Zvara, Á.; Kitajka, K.; Faragó, N.; Puskás, L. G; Microarray Technology, *Acta Biol. Szeged*, 2015, 59, 51–67.
 23. Mmeka, E.; Adesoye, A; Nucleotide Polymorphism (SNP) Markers Discovery within *Musa Spp* (Plantain Landraces, AAB Genome) for Use in Beta Carotene (Provitamin A) Trait Mapping, *Am. J. Biol. life Sci*, 2013, 1 (1), 11–19.
 24. Briones, C; Polymerase Chain Reaction, *Encycl. Astrobiol*, 2016, No. 6.
 25. Abd-elsalam, K. A; Minireview Bioinformatic Tools and Guideline for PCR Primer Design, 2003, 2 (5), 91–95.
 26. Marchesi. R. J. et al; Design and Evaluation of Useful Bacterium-Specific PCR Primers That Amplify Genes Coding for Bacterial 16S rRNA, *Appl. Environ. Microbiol*, 1998, 64 (2), 795–799.
 27. Pingoud, A; Jeltsh A; Structure and Function of type II Restriction Endonuclease, *Nucleic Acids Research*, 2001, 1, No. 18
 28. Berg, H; Restriction Fragment Length Polymorphism Analysis of PCR-Amplified Fragments (PCR-RFLP) and Gel Electrophoresis - Valuable Tool for Genotyping and Genetic Fingerprinting, *Gel Electrophor. - Princ. Basics*, 2012.
 29. Sankar, S.; Ramamurthy, M.; Nandagopal, B.; Sridharan, G; An Appraisal of PCR-Based Technology in the Detection of Mycobacterium Tuberculosis, *Mol. Diagnosis Ther*, 2011, 15 (1), 1–11.
 30. Rojas, M.; et al; Identification of Raw and Heat-Processed Meats from Game Bird Species by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism of the Mitochondrial D-Loop Region, *Poult. Sci*, 2009, 88 (3), 669–679.
 31. Saini, M.; et al; Characterisation of Peacock (*Pavo Cristatus*) Mitochondrial 12S rRNA Sequence and Its Use in Differentiation from Closely Related Poultry Species, *British Poultry Sciences*, 2007, 48 (2), 162–166.
 32. Hennessy, B. T.; Smith, D. L.; et al; Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery, *Nat. Rev. Drug Discov*, 2005, 4 (12), 988–1004.
 33. Lee, P. Y.; Costumbrado, J.; Hsu, C. Y.; Kim, Y. H; Agarose Gel Electrophoresis for the Separation of DNA Fragments, *Journal of Visualized Experiment*, 2012, No. 62, 1–5.
 34. Yilmaz, M.; Ozic, C.; Gok, Ihami; Principles of Nucleic Acid Separation by Agarose Gel Electrophoresis, *Gel Electrophor. - Princ. Basics*, 2012.
 35. Chmielecki, J.; Meyerson, M; DNA Sequencing of Cancer: What Have We Learned? *Annu. Rev. Med.* 2014, 65 (1), 63–79.
 36. Suman. G; Jamil. K; Novel CYP3A4 Gene Polymorphisms in Post Chemo Breast Cancer Patients, 2006, 2(4), 358-366.
 37. National Breast Cancer Institute Official Team, Restriction Fragment Length Polymorphism (RFLP), 2016, <https://www.ncbi.nlm.nih.gov/probe/docs/techrflp/>, diakses pada tanggal 8 Agustus 2019.
 38. Zhou, Y.; Ingelman-Sundberg, M.; Lauschke, V. M; Worldwide Distribution of Cytochrome P450 Alleles: A Meta-Analysis of Population-Scale Sequencing Projects, *Clinical Pharmacology Therapeutics*, 2017, 102 (4), 688–700.